Acrivon Therapeutics, Inc. (ACRV) Live Share Price, Invest From India

Acrivon Therapeutics, Inc. Stock Performance

as on August 25, 2026 at 2:16 pm IST

Day's Low
Day's High
$2.09
Day's Price Range
$2.23
$2.20
5.00%
Downside
1.36%
Upside
52 Week's Low
52 Week's High
$1.27
52-Week Price Range
$3.56
$2.20
42.27%
Downside
61.82%
Upside

Acrivon Therapeutics, Inc. share price movements today

Previous Close: $2.21
Open: $2.19
Volume: 335.9K
Market Cap: $83.5M
Day's Low - High: $2.09 - $2.23
52 Week Low - High: $1.27 - $3.56

Acrivon Therapeutics, Inc. Historical Returns

1 Month Return: + 11.43 %
3 Month Return: + 10.17 %
1 Year Return: + 44.44 %
3 Year Return: -82.34 %
5 Year Return: 0 %

Acrivon Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Acrivon Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$83.5M

EPS (TTM)

-1.88

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.98

Industry PE ratio

-1.5966015625

PEG Ratio

-0.05295665690838641

EBITDA

-78.9M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-70.14%

Acrivon Therapeutics, Inc. Stock Valuation

Track how Acrivon Therapeutics, Inc. P/E has moved over time to understand its valuation trends.

Acrivon Therapeutics, Inc. in the last 5 years

Overview
Trends

Lowest (-13.23x)

December 31, 2021

Industry (-1.60x)

December 31, 2025

Today (-1.19x)

December 31, 2025

Highest (-1.19x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.19x

Acrivon Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Acrivon Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Acrivon Therapeutics, Inc.	BUY	$83.5M	NA	-0.98	0.00%	NA
Revolution Medicines	BUY	$43.7B	669.3%	NA	0.00%	NA
Vertex Pharmaceuticals	BUY	$128.2B	154.86%	29.82	86.04%	NA
Moderna	BUY	$25.3B	-84.24%	-7.98	-12.57%	NA
Regeneron	BUY	$82.7B	24.1%	19.24	84.86%	0.44999999999999996%

Stock Returns calculator for Acrivon Therapeutics, Inc. Stock including INR - Dollar returns

The Acrivon Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Acrivon Therapeutics, Inc. investment value today

Current value as on today

₹1,77,475

Returns

₹77,475

(+77.47%)

Returns from Acrivon Therapeutics, Inc. Stock

₹62,963 (+62.96%)

Dollar Impact

₹14,512 (+14.51%)

Analyst Recommendation on Acrivon Therapeutics, Inc. Stock

Based on 5 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 5 analysts, 100% of analysts recommend a 'BUY' rating for Acrivon Therapeutics, Inc.. Average target price of $11.5

Acrivon Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Acrivon Therapeutics, Inc..

What analysts predicted

80.87%UPSIDE

Target Price

$11.5

Current Price

$2.2

Analyzed by

5 Analysts

Target

$11.50

Acrivon Therapeutics, Inc. target price $11.5, a slight upside of 80.87% compared to current price of $2.2. According to 5 analysts rating.

Indian Investors' Interest in Acrivon Therapeutics, Inc. Stock

Search interest for Acrivon Therapeutics, Inc. Stock has decreased by -57% in the last 30 days, reflecting a downward trend in search activity.

Time period: July 26, 2026 to August 25, 2026

Change:-57% versus previous 30 day period

Acrivon Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	-	-	0	0	0	-	0	0	-
Operating Income	-17	-21	-25	-24	-21	-22	-19	-20	-19	-18
EBITDA	-16	-18	-22	-22	-19	-20	-17	-24	-18	-17
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-16	-18	-22	-22	-19	-21	-18	-18	-19	-17
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-16	-18	-22	-22	-19	-21	-18	-18	-19	-17
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Acrivon Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-
Gross Profit	0	-	-	0	-1	-1
Operating Income	-3	-16	-32	-67	-89	-84
EBITDA	-5	-16	-30	-59	-79	-76
Interest Expense	-	-	-	-	-	-
Depreciation	0	0	0	0	1	1
Income Before Tax	-5	-16	-31	-60	-80	-77
Income Tax Expense	-	-	-	-	-	-
Net Income	-5	-16	-31	-60	-80	-77
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Acrivon Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-16	-18	-22	-22	-19	-21	-18	-18	-19	-17
Operating Cash Flow	-17	-13	-17	-17	-19	-16	-12	-15	-20	-14
Investing Cash Flow	5	-88	16	14	19	19	5	21	13	14
Financing Cash Flow	0	123	-1	0	0	0	0	0	0	7
Change in Cash	-11	21	-2	-3	0	2	-6	6	-7	7

Acrivon Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-5	-16	-31	-60	-80	-77
Operating Cash Flow	-2	-13	-30	-42	-65	-63
Investing Cash Flow	0	0	-141	50	-51	66
Financing Cash Flow	2	112	101	-1	121	0
Change in Cash	0	98	-70	6	3	1

Mutual Funds that own Acrivon Therapeutics, Inc. Stock

Check out the Mutual Funds with significant holdings in Acrivon Therapeutics, Inc..

Funds	Holdings	Shares Held
VANGUARD INDEX FUNDS	1.686929%	722035
Fidelity Concord Street Trust	0.415885%	178006
Bridgeway Funds, Inc.	0.359798%	154000
Nationwide Mutual Funds	0.069621%	29799
TIAA-CREF Funds	0.027618%	11821

See all

Global Institutional Holdings in Acrivon Therapeutics, Inc.

Funds	Holdings
Peter Kolchinsky	19.49%
Vanguard	2.18%
iShares	0.17%
Bridgeway	0.14%
Felix Baker	0.05%

Insights on Acrivon Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 1 month, ACRV stock has moved up by 37.5%
NO EFFECT
Against Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 538.4% return, outperforming this stock by 620.1%
NO EFFECT
Against Peers
In the last 1 year, Revolution Medicines, Inc. Common Stock has given 493.2% return, outperforming this stock by 427.8%

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Organisation	Acrivon Therapeutics, Inc.
Headquarters	480 Arsenal Way, Watertown, MA, United States, 02472
Industry	Biotechnology
CEO	Dr. Peter Blume-Jensen M.D., Ph.D.
E-voting on shares	Click here to vote

Key Management of Acrivon Therapeutics, Inc.

Name	Title
Ms. Mary-Alice Miller J.D.	Chief Legal Officer & Corporate Secretary
Dr. Jesper V. Olsen Ph.D.	Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board
Dr. Peter Blume-Jensen M.D., Ph.D.	Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
Dr. Eric J. Devroe Ph.D.	Chief Operating Officer
Dr. Adam D. Levy M.B.A., Ph.D.	CFO & Principal Financial Officer
Dr. Erick Gamelin M.D., Ph.D.	Chief Development Officer
Mr. Joon Jung Ph.D.	VP & Head of Data Science
Ms. Kristina Masson M.B.A., Ph.D.	Co-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director
Ms. Katharine Peterson CPA	Vice President of Finance & Accounting
Mr. Bruce Close	Vice President of Quality & Compliance

FAQs

What is Acrivon Therapeutics, Inc. share price today?

Acrivon Therapeutics, Inc. share price today is $2.20 as on August 25, 2026 at 8:46 am IST at the close of the market. Acrivon Therapeutics, Inc. share today touched a day high of $2.23 and a low of $2.09.

What is the 52 week high and 52 week low for Acrivon Therapeutics, Inc. share?

Acrivon Therapeutics, Inc. share touched a 52 week high of $3.56 on January 7, 2026 and a 52 week low of $1.27 on March 30, 2026. Acrivon Therapeutics, Inc. stock price today i.e. August 25, 2026 at 8:46 am IST is closed at $2.20,which is 38.20% down from its 52 week high and 73.23% up from its 52 week low.

What is Acrivon Therapeutics, Inc.'s market capitalisation today?

Acrivon Therapeutics, Inc. market capitalisation is $0.00T as on August 25, 2026 at 8:46 am IST.

How to invest in Acrivon Therapeutics, Inc. Stock (ACRV) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Acrivon Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Acrivon Therapeutics, Inc. Shares that will get you 0.6818 shares as per Acrivon Therapeutics, Inc. share price of $2.20 per share as on August 25, 2026 at 8:46 am IST.

What is the minimum amount required to buy Acrivon Therapeutics, Inc. Stock (ACRV) from India?

Indian investors can start investing in Acrivon Therapeutics, Inc. (ACRV) shares with as little as ₹95.41 or $1 (as of August 25, 2026 at 5:43 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹954.10 in Acrivon Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on August 25, 2026 at 5:43 pm IST). Based on Acrivon Therapeutics, Inc. share’s latest price of $2.20 as on August 25, 2026 at 8:46 am IST, you will get 4.5455 shares of Acrivon Therapeutics, Inc.. Learn more about fractional shares .